Reset filter
Nyckelord
Chemotherapy, Adjuvant ×
Visa mer Nyckelord
Innehållsförteckning
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Valda datamodeller

Du måste vara inloggad för att välja flera datamodeller, ladda ner dem eller analysera dem.

63 Sökresultat.
Relevans Bedömning Nya först Gamla först

Predictors of Therapeutic Response in Ovarian Carcinoma NCT01391351 - Eligibility Criteria

- 6/23/19 - 1 Formulär, 2 Item-grupper, 13 Dataelement, 1 Språk
Item-grupper: Inclusion Criteria, Exclusion Criteria
Search for Predictors of Therapeutic Response in Ovarian Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01391351 In order to search for predictors of response to chemotherapy in patients with ovarian carcinoma of the ovary, the fallopian tube or peritoneal serous-type advanced stage, we will define the comparative profiles of miRNA expression of serum polymorphisms and determine differential in 2 patient populations (with or without recurrence 6 months after completion of chemotherapy) with (i) the miRNA profile of serum before treatment and (ii) identification of polymorphisms or SNP (Single Nucleotide Polymorphism) in particular genes involved in the metabolism of chemotherapy agents In the case of miRNA, expression profiles will also be studied during the first course in response to chemotherapy. Indeed, the miRNA profile of serum may be different at baseline among the 2 types of populations (or non-recurrence at 6 months).

Breast Cancer Swedish National Quality Registry - Pre- or post operative adjuvant oncological treatment

- 1/12/18 - 1 Formulär, 6 Item-grupper, 33 Dataelement, 2 Språk
Item-grupper: National Quality Register for Breast Cancer, Pre- or post operative adjuvant oncological treatment, Chemotherapy, Radiotherapy, Endocrine treatment, Antibody therapy, Bisphosphonates therapy
Description of registry: The aim of the National Quality Registry for Breast Cancer is to: -in an objective and standardised manner, monitor the continuum of care from diagnosis to any recurrence and death -enable the identification of regional differences -collectively relate to current guidelines and quality targets set by specialist associations and the National Board of Health and Welfare -facilitate research and developments in breast cancer. Pre- or post operative adjuvant oncological treatment Source: http://www.cancercentrum.se/samverkan/cancerdiagnoser/brost/kvalitetsregister/dokument/ Facts Owner: Kerstin Sandelin surgeon, Karolinska University Hospital, Solna kerstin.sandelin@sll.se

Concomitant Therapy GIMEMA CML0408 NCT00769327 - Concomitant Therapy

- 11/29/17 - 1 Formulär, 1 Item-grupp, 4 Dataelement, 2 Språk
Item-grupp: Concomitant pharmacological therapies
RATIONALE: Nilotinib and imatinib m esylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Concomitant Therapy Form.

Visit 8 GIMEMA CML0408 NCT00769327 - Visit 8

- 11/29/17 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 2 Språk
Item-grupper: Physical Examination, IMATINIB, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 8 form.

Visit 14 GIMEMA CML0408 NCT00769327 - Visit 14

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 14 form.

Visit 15 GIMEMA CML0408 NCT00769327 - Visit 15

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 15 form.

Visit 11 GIMEMA CML0408 NCT00769327 - Visit 11

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 11 form.

Visit 12 GIMEMA CML0408 NCT00769327 - Visit 12

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 12 form.

Visit 9 GIMEMA CML0408 NCT00769327 - Visit 9

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 9 form.

Visit 6 GIMEMA CML0408 NCT00769327 - Visit 6

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 6 form.

Visit 4 GIMEMA CML0408 NCT00769327 - Visit 4

- 11/29/17 - 1 Formulär, 2 Item-grupper, 23 Dataelement, 2 Språk
Item-grupper: Physical Examination, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 4 form.

Visit 2 GIMEMA CML0408 NCT00769327 - Visit 2

- 11/28/17 - 1 Formulär, 3 Item-grupper, 28 Dataelement, 2 Språk
Item-grupper: Physical Examination, NILOTINIB, Complete Blood Count
RATIONALE: Nilotinib and imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the visit 2 form.

Kontakt

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Hjälp

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial